Title:
A biological marker useful for immunological medical treatment of cancer
Document Type and Number:
Japanese Patent JP6059405
Kind Code:
B2
Abstract:
Methods are disclosed that are based on the finding that serum and plasma levels of eotaxin, MIP1α, and CRP act as important biomarkers that are useful for determining the feasibility in instigating immunotherapeutic treatment of cancer when immunizing with the GV1001 peptide (EARPALLTSRLRFIPK; derived from human telomerase protein), optionally when combined with state of the art combination treatment with Gemcitabine and Capecitabine. In particular, the present invention provides methods for determining whether patients should be treated GV1001 and for determining whether instigated treatment should be continued.
Inventors:
Kim Sanchee
Application Number:
JP2016518278A
Publication Date:
January 11, 2017
Filing Date:
June 05, 2014
Export Citation:
Assignee:
Gembacks and Frog Company, Limited
Kim Sanchee
Kim Sanchee
International Classes:
A61K38/00; A61K38/08; A61P29/00; A61P35/00; C07K7/00; G01N33/68
Other References:
Journal of Clinical Oncology,2013年 5月20日,Vol.31,No.18,SUPPL.1.AbstractNumber:LBA404.
British Journal of Cancer,2006年,Vol.95,No.11,pp.1474-1482.
British Journal of Cancer,2006年,Vol.95,No.11,pp.1474-1482.
Attorney, Agent or Firm:
Atsushi Aoki
Takashi Ishida
Fukumoto product
Tetsuji Koga
Yoichi Watanabe
Ryotaro Takei
Takahide Sasaki
Takashi Ishida
Fukumoto product
Tetsuji Koga
Yoichi Watanabe
Ryotaro Takei
Takahide Sasaki